MedPath

Karappan thailam (internal) and nunapattai thailam(external) for karappan(Atopic dermatitis) for children

Phase 2
Not yet recruiting
Conditions
Atopic dermatitis, unspecified,
Registration Number
CTRI/2022/11/047404
Lead Sponsor
Government siddha medical college
Brief Summary

This is interventional study in which 40 patients will be selected based on inclusion and exclusion criteria . For internal karappan ennai and for external  nunapattai thailam  will be given in the dosage of 5 ml OD for internal and the external application of nunapattai thailam opn the affected area for 21 days of duration .The data related to the study will be collected from each patients depends on the reduction  of symptoms and changes in the investigations .All collected data will be entered in to MS Excel software . STATA software will be used to perform statistical analysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Itching,erythema,papules,vesicles,oozing,crusting, scaling and lichenification.

Exclusion Criteria

Psoriasis,scabies,photo dermatitis,ichthyosis vulgaris,pityriasis alba.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in EASI score(Eczema area severity index)21 Days
Reduction in clinical symptoms like itching,papules ,pustules ,oozing,scaling,lichenification21 Days
Photos of the patient before and after treatment for the evidence of clinical improvement21 Days
Secondary Outcome Measures
NameTimeMethod
It is assessed by comparing the safety parameters before and after treatment.21 days

Trial Locations

Locations (1)

Government siddha medical college and hospital

🇮🇳

Chennai, TAMIL NADU, India

Government siddha medical college and hospital
🇮🇳Chennai, TAMIL NADU, India
MRAHUL
Principal investigator
7010819169
rahulmathan20@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.